成人脓毒症幸存者中既存糖尿病与长期心血管结局:一项基于人群的队列研究
该基于人群的队列研究纳入加拿大安大略省2008-2017年首次脓毒症相关住院后存活、无既存心血管疾病的成人,按1:1倾向评分匹配既存糖尿病(任何类型)与无糖尿病患者各78,638例,随访至出院后5年或2018年3月。既存糖尿病者主要心血管复合终点风险更高(HR 1.25;95%CI 1.22-1.29),其中心肌梗死HR 1.40(95%CI 1.34-1.47)、卒中HR 1.24(95%CI 1.18-1.29)。既存糖尿病修饰了脓毒症与心血管疾病的关联:有糖尿病者脓毒症效应风险差2.3%(95%CI 2.0-2.6),无糖尿病者1.8%(95%CI 1.6-2.0)。提示对脓毒症幸存者中的糖尿病患者需关注长期心血管风险。
要点
- 成人脓毒症幸存者中,既存糖尿病者长期主要心血管复合终点风险高于无糖尿病者(HR 1.25;95%CI 1.22-1.29)。
- 既存糖尿病者心肌梗死风险HR 1.40(95%CI 1.34-1.47),卒中风险HR 1.24(95%CI 1.18-1.29)。
- 糖尿病修饰脓毒症与心血管疾病的关联:有糖尿病者脓毒症效应风险差2.3%(95%CI 2.0-2.6),无糖尿病者1.8%(95%CI 1.6-2.0)。
- 匹配队列平均年龄71岁,55%为女性;糖尿病诊断中位病程9.8年,平均HbA1c 7.1%。
- 作者结论:与无脓毒症患者相比,脓毒症后心血管事件的绝对风险增加在糖尿病患者中更高,即糖尿病放大了脓毒症诱导的心血管风险。
适用人群与场景
- 加拿大安大略省2008-2017年首次脓毒症相关住院后存活的成人,且无既存心血管疾病。
- 暴露为既存糖尿病(任何类型),按1:1倾向评分匹配至脓毒症住院但无既存糖尿病的患者。
- 随访自出院日期起至结局发生或研究期结束(2018年3月),最长5年。
研究设计与关键结果
- 研究类型:基于人群的队列研究,加拿大安大略省2008-2017年;既存糖尿病患者78,638例与无糖尿病患者1:1倾向评分匹配。
- 匹配队列平均年龄71岁,55%为女性;糖尿病诊断中位病程9.8年,平均HbA1c 7.1%。
- 主要终点(心肌梗死、卒中、心血管死亡复合):既存糖尿病者较无糖尿病者HR 1.25(95%CI 1.22-1.29)。
- 心肌梗死:HR 1.40(95%CI 1.34-1.47);卒中:HR 1.24(95%CI 1.18-1.29)。
- 次要分析:既存糖尿病修饰脓毒症与心血管疾病的关联,有糖尿病者脓毒症效应风险差2.3%(95%CI 2.0-2.6),无糖尿病者风险差1.8%(95%CI 1.6-2.0)。
证据类型、等级与局限
- 证据类型:基于人群的队列研究;采用倾向评分匹配及病因特异性Cox比例风险模型(稳健标准误)估计HR及95%CI。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与无脓毒症患者相比,脓毒症后心血管事件的绝对风险增加在糖尿病患者中更高,即糖尿病放大了脓毒症诱导的心血管风险。
- 原文结论未据此给出具体推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis survivors are at elevated risk for cardiovascular disease during long-term follow-up. Whether diabetes influences cardiovascular risk after sepsis survival remains unknown. We sought to describe the association of diabetes with long-term cardiovascular outcomes in adult sepsis survivors.
METHODS: Population-based cohort study in the province of Ontario, Canada (2008-2017). Adult survivors of a first sepsis-associated hospitalization, without pre-existing cardiovascular disease, were included. Main exposure was pre-existing diabetes (any type). The primary outcome was the composite of myocardial infarction, stroke, and cardiovascular death. Patients were followed up to 5 years from discharge date until outcome occurrence or end of study period (March 2018). We used propensity score matching (i.e., 1:1 to patients with sepsis but no pre-existing diabetes) to adjust for measured confounding at baseline. Cause-specific Cox proportional hazards models with robust standard errors were used to estimate hazard ratios (HR) alongside 95% confidence intervals (CI). A main secondary analysis evaluated the modification of the association between sepsis and cardiovascular disease by pre-existing diabetes.
RESULTS: 78,638 patients with pre-existing diabetes who had a sepsis-associated hospitalization were matched to patients hospitalized for sepsis but without diabetes. Mean age of patients was 71 years, and 55% were female. Median duration from diabetes diagnosis was 9.8 years; mean HbA1c was 7.1%. Adult sepsis survivors with pre-existing diabetes experienced a higher hazard of major cardiovascular disease (HR 1.25; 95% CI 1.22-1.29)-including myocardial infarction (HR 1.40; 95% CI 1.34-1.47) and stroke (HR 1.24; 95% CI 1.18-1.29)-during long-term follow-up compared to sepsis survivors without diabetes. Pre-existing diabetes modified the association between sepsis and cardiovascular disease (risk difference: 2.3%; 95% CI 2.0-2.6 and risk difference: 1.8%; 95% CI 1.6-2.0 for the effect of sepsis-compared to no sepsis-among patients with and without diabetes, respectively).
CONCLUSIONS: Sepsis survivors with pre-existing diabetes experience a higher long-term hazard of major cardiovascular events when compared to sepsis survivors without diabetes. Compared to patients without sepsis, the absolute risk increase of cardiovascular events after sepsis is higher in patients with diabetes (i.e., diabetes intensified the higher cardiovascular risk induced by sepsis).
参考来源
- Angriman F, Lawler PR, Shah BR, et al. Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors: a population-based cohort study. Crit Care. 2023. PMID: 37525272. doi:10.1186/s13054-023-04586-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。